INO-3107 Shows Significant Long-Term Benefits in Treating Recurrent Respiratory Papillomatosis with Reduced Surgeries and Improved Response Rates.

INO-3107, a DNA medicine developed by INOVIO, has shown promising long-term results in treating Recurrent Respiratory Papillomatosis (RRP). The Overall Response Rate improved to 86% in Year 2 from 72% in Year 1, and the Complete Response rate nearly doubled to 50% in Year 2 from 28% in Year 1. Mean surgeries reduced by 78% from 4.1 pre-treatment to 0.9 in Year 2. INO-3107 has earned Orphan Drug and Breakthrough Therapy designations from the FDA.

A recent study published in The Laryngoscope has demonstrated the long-term efficacy of INOVIO's DNA medicine, INO-3107, in treating Recurrent Respiratory Papillomatosis (RRP). The retrospective trial, involving 28 patients from INOVIO's initial Phase 1/2 trial, showed significant improvements in clinical outcomes over a median follow-up period of 2.8 years.

The Overall Response Rate (ORR) improved to 86% at the end of the second 12-month period (Year 2) compared to 72% observed at the end of the initial 12-month Phase 1/2 trial (Year 1). The Complete Response (CR) rate nearly doubled to 50% in Year 2 from 28% in Year 1. The mean number of surgeries needed to control RRP dropped from 4.1 surgeries per year prior to treatment to 0.9 surgeries per year in Year 2, representing a 78% reduction [1].

INO-3107, an investigational DNA medicine designed to elicit an antigen-specific T cell response against both HPV-6 and HPV-11 proteins, has shown remarkable long-term efficacy. The drug has received both Orphan Drug and Breakthrough Therapy designations from the FDA, indicating its potential to significantly impact the treatment of RRP [1].

The FDA's accelerated approval program, combined with INOVIO's CE-marked CELLECTRA® delivery device, positions INO-3107 as a promising candidate for the market. The company's DNA medicines platform, which includes precisely designed DNA plasmids delivered by the CELLECTRA device, offers a unique approach to treating HPV-related diseases, cancer, and infectious diseases [1].

INOVIO's focus on developing and commercializing DNA medicines underscores its commitment to innovative healthcare solutions. The company's technology optimizes the design and delivery of DNA medicines, providing a potential breakthrough in the treatment of RRP and other diseases [1].

References:
[1] https://ir.inovio.com/news-releases/news-releases-details/2025/Data-Published-in-The-Laryngoscope-shows-INO-3107-Resulted-in-Long-Term-Surgery-Reduction-in-Recurrent-Respiratory-Papillomatosis-RRP/default.aspx